Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523682 | 0.84 | PDE5A (0.77) | PDE5AMAPTALDH1A1 | |
| SCHEMBL12494570 | 0.70 | PDE5A (1.00) | PDE5AMAPTALDH1A1 | |
| SCHEMBL11956702 | 0.69 | PDE5A (0.52) | PDE5AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL12524149 | 0.66 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524143 | 0.66 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524159 | 0.66 | PDE5A (1.00) | PDE5A | |
| SCHEMBL15803419 | 0.66 | PDE5A (0.69) | PDE5AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL15803422 | 0.66 | MAPT (0.62) | PDE5AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30873727 | 0.66 | CYP1A2 (0.57) | MEN1KMT2AMAPT | |
| Butane SCHEMBL27774502 | 0.65 | TP53 (0.83) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388139-B2 | Derivatives of celeboxib, use thereof and preparation thereof | GERMAN UNIVERSITY (EG) | 2016-07-12 | — | — | US | disclosed |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2014-06-19 | — | — | US | disclosed |
| WO-2012125884-A1 | DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | PDE5A, PDE3A, PDE3B | PDE5A 1/4885MEN1 1839/4885KMT2A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.